Fig. 5: Treatment with adiponectin-expressing tTreg precursors alleviates HFD-induced metabolic abnormalities.
From: Adiponectin-expressing Treg facilitate T lymphocyte development in thymic nurse cell complexes
Vehicle or adiponectin-expressing EGFP+ cells [30000 cells/mouse] isolated from Adn-Cre/ROSAmT/mG mice were injected via tail vein into 4-week-old WT mice, which were then subjected to HFD feeding for another 12 weeks. a At the end of treatment, the gain of body weight and the percentage body fat mass composition were calculated for comparison. b After 10- and 12 weeks of HFD, intraperitoneal glucose (left) and insulin (right) tolerance tests were performed as described in the Methods. Results are presented as fold changes against the glucose levels at time zero for comparison. c Indirect calorimetry was used to examine the VO2, VCO2, energy expenditure, and RER as described in the Methods. The 24-h average values were calculated for comparison. d The fasting blood glucose and serum insulin, triglyceride or cholesterol levels were measured after 12 weeks of HFD feeding for comparison. Data are presented as mean ± SEM. *, P < 0.05 and **, P < 0.01 vs corresponding vehicle control groups (n = 6 biologically independent samples from different animals of independent experiment).
